Rimtuzalcap

Research use only, not for human use.

Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels).

Rimtuzalcap (CAD-1883) is a first-in-class selective positive allosteric modulator of small-conductance calcium-activated potassium channels (SK channels). Rimtuzalcap can be used for the research of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA).(In Vitro):Rimtuzalcap (Compound 1) is a small molecule modulator of potassium ion channels showing great therapeutic potential for treating a variety of diseases characterized by dysfunction of potassium ion channels and dysfunction from other causes which influence these potassium channels.(In Vivo):Rimtuzalcap (CAD-1883) reduces the firing rate of Purkinje cells by approximately 40%, consistent with the anticipated therapeutic mechanism of positive allosteric modulation of SK channels. Sequential bath application of 1 or 3 μM CAD-1883 results in a partial reversal of the increased coefficient of variation of the interspike interval which is seen in cerebellar slices from 11-month-old spinocerebellar ataxia-2 58Q mice.

CAD-1883

Cell Cycle/DNA Damage

Potassium Channel

human glucagon receptor

——

——

2167246-24-2

378.4

C18H24F2N6O

>98% (HPLC)

——

Cc1ccn(n1)-c1nc(NC2CCC(F)(F)CC2)cc(n1)N1CCOCC1

——

(-20℃)

With Ice Pack

≥ 2 years